The Impact of Metabolic and Bariatric Surgery on Nutritional Status and Sarcopenia: A Narrative Overview of Underlying Mechanisms, Clinical Implications, and Prevention Strategies
The recent literature highlights a high and increasing prevalence of muscle loss after surgery, driven by reduced protein intake, micronutrient deficiencies, hormonal changes, and decreased mechanical loading.
Abstract
Bariatric surgery is the most effective treatment for severe obesity, leading to significant and sustained weight loss and improvement in metabolic comorbidities. However, it is also associated with substantial changes in body composition and nutritional status, including the risk of sarcopenia and sarcopenic obesity. This review aims to summarize current evidence on the interplay between metabolic and bariatric surgery, nutritional alterations, and skeletal muscle health. The recent literature highlights a high and increasing prevalence of muscle loss after surgery, driven by reduced protein intake, micronutrient deficiencies, hormonal changes, and decreased mechanical loading. Despite these challenges, improvements in metabolic health and physical function are often observed, suggesting a complex relationship between muscle mass and functional outcomes. A multidisciplinary approach, including nutritional optimization and structured exercise interventions, is essential to mitigate muscle loss and function and improve long-term outcomes. Further research is needed to standardize diagnostic criteria and develop targeted strategies for prevention and management.
Introduction and purpose. Sarcopenic obesity (SO) is defined by the coexistence of excess adiposity and reduced muscle mass and function and is associated with disability, frailty, cardiometabolic disease, and increased mortality. This review aims to summarize current evidence on the definition and diagnosis of SO, ass...
A. Wolszczak, Weronika Martynowska, Michał Hajt et al.· International Journal of Inn...· 0 citations
Introduction. Obesity is a chronic, complex, relapsing disease requiring long-term, individualized management. Incretin-based pharmacotherapy has increased the potential for clinically meaningful weight loss, but maintaining outcomes and limiting adverse body-composition changes also require dietary therapy and physica...
M. Iwaszko, Marcelina Skajewska, Julia Stojko et al.· Quality in Sport· 0 citations
Sarcopenia is defined as a loss of muscle mass and strength. It represents a frequent and multifactorial complication in patients with gastrointestinal cancers, resulting from the combined effects of malnutrition, chronic inflammation, metabolic alterations, and reduced physical activity level. Its assessment relies on...
Géraldine M. Camilleri, Eléa Janvier, F. Pigneur et al.· Bulletin du Cancer· 0 citations
This narrative review synthesizes current evidence on lifestyle, pharmacological, surgical, and multimodal interventions targeting muscle strength, body composition, and functional capacity in HFpEF with sarcopenia and/or obesity. Exercise, particularly concurrent endurance and resistance training protocols, improve ae...
K. Prokopidis, Aniket S. Joshi, Søren Gam et al.· Current Heart Failure Report...· 0 citations
Background: Obesity is associated with impaired skeletal muscle health and sarcopenic obesity. GLP-1-based pharmacotherapies induce weight loss, but accompanying reductions in fat-free or lean mass raise concerns about skeletal muscle loss. Conversely, reductions in adiposity, inflammation, insulin resistance, and intr...
Sarcopenic obesity is an emerging geriatric syndrome defined by the simultaneous presence of reduced skeletal muscle mass and function alongside excess adiposity. As populations age and obesity prevalence rises, this condition has grown in clinical importance, carrying risks of frailty, falls, disability, metabolic syn...
Harishchandra Chaudhari, Gaurav Chaudhary, Y. Gaikwad et al.· Geriatric Care· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.